**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 80323

**Manuscript Type:** MINIREVIEWS

**Endoscopic advances in the management of gastric cancer and premalignant gastric conditions**

Park E *et al*. Endoscopic advances in gastric cancer

Erica Park, Makoto Nishimura, Priya Simoes

**Erica** **Park,** **Priya** **Simoes,** Division of Gastroenterology and Hepatology, Mount Sinai Morningside and West, New York, NY 10025, United States

**Makoto** **Nishimura,** Gastroenterology, Hepatology and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States

**Author contributions:** Park E and Simoes P wrote the manuscript; Nishimura M provided figures for the manuscript; and all authors have read and approved the final manuscript.

**Corresponding author: Erica Park, MD, Academic Fellow,** Division of Gastroenterology and Hepatology, Mount Sinai Morningside and West, 1111 Amsterdam Ave, Stuy 12, New York, NY 10025, United States. ericakimberlypark@gmail.com

**Received:** September 23, 2022

**Revised:** December 17, 2022

**Accepted:** February 10, 2023

**Published online:** March 16, 2023

**Abstract**

Gastric cancer is the fifth most common cancer and in 2018, it was the third most common cause of cancer-related deaths worldwide. Endoscopic advances continue to be made for the diagnosis and management of both early gastric cancer and premalignant gastric conditions. In this review, we discuss the epidemiology and risk factors of gastric cancer and emphasize the differences in early *vs* late-stage gastric cancer outcomes. We then discuss endoscopic advances in the diagnosis of early gastric cancer and premalignant gastric lesions. This includes the implementation of different imaging modalities such as narrow-band imaging, chromoendoscopy, confocal laser endomicroscopy, and other experimental techniques. We also discuss the use of endoscopic ultrasound in the diagnosis and staging of early gastric cancer. We then discuss the endoscopic advances made in the treatment of these conditions, including endoscopic mucosal resection, endoscopic submucosal dissection, and hybrid techniques such as laparoscopic endoscopic cooperative surgery. Finally, we comment on the current suggested recommendations for surveillance of both gastric cancer and its premalignant conditions.

**Key Words:** Gastric cancer; Premalignant gastric conditions; Endoscopy; Narrow-band imaging; Endoscopic mucosal resection; Endoscopic submucosal dissection; Gastric cancer surveillance

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Park E, Nishimura M, Simoes P. Endoscopic advances in the management of gastric cancer and premalignant gastric conditions. *World J Gastrointest Endosc* 2023; 15(3): 114-121

**URL:** <https://www.wjgnet.com/1948-5190/full/v15/i3/114.htm>

**DOI:** https://dx.doi.org/10.4253/wjge.v15.i3.114

**Core Tip:** Consider screening for gastric cancer in appropriate patient populations, as early gastric cancer outcomes are associated with improved survival. Use of different imaging modalities during endoscopy such as narrow-band imaging may improve detection of gastric cancer and premalignant gastric conditions. Endoscopic mucosal resection and submucosal dissection have shown favorable long-term outcomes. While there are no established evidence-based gastric cancer surveillance guidelines in the United States, other studies have suggested annual surveillance after gastric cancer resection. Endoscopic surveillance of premalignant gastric conditions may be considered, with closer intervals in patients with evidence of dysplasia.

**INTRODUCTION**

Globally, gastric cancer is the fifth most common cancer, with an estimated 1 million new cases annually[1-3]. In 2020, it was the fourth most common cause of cancer-related deaths worldwide[1-3]. In recent years, many endoscopic advances have been made for both the diagnosis and therapy of gastric cancer. In this article, we review the endoscopic tools used for the diagnosis and treatment of gastric cancer and premalignant gastric conditions. First, we discuss briefly the epidemiology of gastric cancer and outline the differences in outcomes for early-stage *vs* late-stage gastric cancer. We then review the endoscopic approaches in the diagnosis and treatment of gastric cancer and premalignant conditions. Finally, we review the current guidelines for endoscopic surveillance of gastric cancer and premalignant conditions.

***Epidemiology, risk factors, and high-risk populations***

According to the International Agency for Research on Cancer GLOBOCAN project, there were over 1 million new cases of gastric cancer and 768793 deaths from gastric cancer in 2020[4]. The majority of cases of gastric cancer are found in East Asia such as Japan and Korea, as well as Eastern Europe and South America. It is also more highly associated with the male sex, as well as with increasing age[1]. Other risk factors include low socio-economic status, cigarette smoking, alcohol use, pernicious anemia, and autoimmune gastritis[5]. Obesity and gastroesophageal reflux disease are associated with an increased risk of specifically gastric cardia cancer[2].

Infection with *Helicobacter pylori* (*H. pylori*) is a significant cause of gastric cancer[6]. Chronic infection may lead to inflammatory mucosal changes including atrophic gastritis and ultimately intestinal metaplasia[7]. The risk of gastric cancer in patients with *H. pylori* may also be increased with salted food intake, as there is thought to be a synergistic effect. Treatment of *H. pylori* may reduce the risk of the development of gastric cancer, and earlier treatment of this infection has been associated with risk reduction of gastric cancer[1].

***Early vs late-stage gastric cancer outcomes***

Overall, outcomes for gastric cancer are poor, especially in advanced stages[7,8]. Correa’s cascade describes the development from atrophic gastritis to intestinal metaplasia, dysplasia, and ultimately invasive gastric adenocarcinoma[9]. Each step in this cascade offers an opportunity to screen and perform surveillance in order to arrest the development of gastric cancer. The implementation of gastric cancer screening programs in countries with a high incidence of gastric cancer such as Japan and South Korea has demonstrated that earlier diagnosis leads to improved survival[7]. The biennial screening program in South Korea has led to an increase in the diagnosis of early gastric cancer from 39% to 73%, as well as an increase in 5-year survival from 46% to 75%[6]. The difference in survival between early and late stage gastric cancer emphasizes the importance of early diagnosis and treatment.

**ENDOSCOPIC ADVANCES IN THE DIAGNOSIS OF EARLY GASTRIC CANCER AND PREMALIGNANT GASTRIC LESIONS**

***White-light endoscopy***

Conventional endoscopic evaluation of the stomach is performed with white-light endoscopy. When performing endoscopy with white-light imaging, it is recommended to take sufficient time to observe the stomach. Prior studies have demonstrated that endoscopists who took more time to observe the stomach closely detected a greater number of early gastric cancer lesions[10]. The use of defoaming agents such as simethicone to wash the stomach during evaluation may also improve visibility of the stomach lining[10]. The sensitivity of white-light endoscopy for detecting gastric cancer and premalignant lesions has been reported to be anywhere between 30%-70%[11-13]. Additionally, there are now suggested standard mapping protocols in place in order to carefully examine the entire gastric mucosa and ensure that no areas were not viewed under white-light endoscopy[14]. In recent years, other methods of endoscopic visualization have been developed in hopes of improving the diagnosis of gastric cancer.

***Chromoendoscopy***

In chromoendoscopy, indigo carmine or a similar stain is applied topically to the mucosa to help improve identification of gastric cancer or premalignant gastric lesions. Early prospective studies suggest that the use of chromoendoscopy aids in the diagnosis of gastric neoplasia compared to conventional endoscopy[15]. Prior meta-analysis of the diagnostic efficacy of chromoendoscopy suggests that there is an increased diagnostic efficacy and detection of early gastric cancer and premalignant gastric conditions, with a sensitivity of 90% and specificity of 82%[16]. However, it is important to note that no randomized controlled trials have yet been performed to evaluate chromoendoscopy.

***Narrow-band imaging***

In narrow-band imaging (NBI), wavelengths of light used for visualization are limited to a specific band. This allows for improved visualization of the architecture of the mucosa[14,17]. NBI is now used as part of a diagnostic algorithm known as magnifying endoscopy simple diagnostic algorithm for early gastric cancer for classifying early gastric cancer. With the use of NBI, the lesion is evaluated for a demarcation line (DL). If a DL is present, the lesion is then evaluated for an irregular microvascular pattern (IMVP) and an irregular micro surface pattern (IMSP). If the lesion has either an IMVP or IMSP, the diagnosis of early gastric cancer is made[18].

The data for NBI in the diagnostic efficacy and detection of gastric cancer and premalignant gastric lesions is variable. For gastric cancer specifically, there does not appear to be a significant difference in diagnostic yield[19]. However, prior studies indicate that NBI may improve detection of premalignant lesions such as intestinal metaplasia. One randomized controlled trial revealed that non-magnifying NBI had a significantly higher detection rate than white-light endoscopy in the diagnosis of intestinal metaplasia, but not gastric cancer[20]. In a systematic review of ten studies (eight prospective studies and two retrospective studies), NBI appeared to significantly increase the detection of intestinal metaplasia[21,22]. Use of NBI should thus be considered in high risk populations to evaluate for premalignant gastric lesions.

***Confocal laser endomicroscopy***

Confocal laser endomicroscopy is an endoscopic technique that uses a low-power laser to obtain very high magnification of the mucosal layer of the gastrointestinal tract. Prior studies including meta-analyses evaluating the diagnostic value of confocal laser endomicroscopy suggest that CLE provides high sensitivity and specificity for the diagnosis of gastric cancer[23,24]. CLE also appears to have a high sensitivity and specificity in the diagnosis of premalignant gastric lesions. A meta-analysis of four studies including 218 patients and 579 lesions evaluating CLE for the diagnosis of intestinal metaplasia showed a pooled sensitivity of 97% and specificity of 94%[23].

***Other experimental imaging techniques***

Flexible spectral imaging color enhancement (FICE) is another technique with the potential to detect early gastric cancer. In FICE, a narrow bandwidth is obtained from a white-light image without optical filters. This allows for the possible visualization of laminar structures and blood flow in the gastrointestinal mucosa that has been altered by inflammation or malignancy, which will appear as high contrast compared to normal mucosa[25]. Prior studies have suggested that FICE is helpful in distinguishing between non-neoplastic and neoplastic lesions of the stomach[26]. However, FICE is limited in visualization of the mucosal microvasculature of the tumor surface, and visualization may need to be supplemented with additional imaging techniques[25].

Artificial intelligence is a growing field in gastroenterology and has shown efficacy in the detection of many different gastrointestinal lesions. Initial studies of neural networks generated from endoscopic images under both white-light endoscopy and NBI show high sensitivity for both methods in detecting lesions[27,28]. Real-time artificial intelligence detection of gastric lesions has yet to be studied.

***Endoscopic ultrasound***

Endoscopic ultrasound (EUS) allows for assessment of the depth of gastric cancer as it is able to distinctly identify the layers of the stomach[29]. Ultrasound can be achieved using the linear or radial transducers on the endoscope or with a through-the-scope ultrasound catheter probe. The five layers of the gastric wall are identified by their alternating hyperechoic and hypoechoic appearance[29]. EUS therefore is utilized to determine the T category of staging according to the TNM classification. A query of the Surveillance, Epidemiology, and End Results-Medicare claims database performed in 2016 suggested that patients who underwent EUS were more likely to receive National Comprehensive Cancer Network recommended care such as perioperative chemotherapy[30]. Prior meta-analysis of 54 clinical studies suggests that EUS is successfully able to differentiate T1 and T2 stages from T3 and T4 stages, with reported sensitivity of 86% and specificity of 91%[31]. Specifically, EUS has been reported to distinguish T1 from more advanced stages with a sensitivity of 83% and specificity of 96%[31]. However, there was significant heterogeneity among the studies included, with some studies using older TNM classification systems. Factors that appear to decrease EUS accuracy include larger cancer diameter, ulceration, undifferentiated histology, and proximal location[31,32]. Further studies are needed to evaluate the staging accuracy of EUS based on the updated TNM classification system.

EUS is also a modality to help determine nodal involvement of gastric cancer. Larger size of the node, sharp margins, and hypoechoic pattern may help endosonographers determine lymph node involvement. Prior meta-analysis suggests that the sensitivity and specificity of EUS for the assessment of nodal involvement is less than for the T category of staging, with only 69% sensitivity and 84% specificity[29,31]. Similar to T category of staging, there was a large heterogeneity of studies included.

**ENDOSCOPIC ADVANCES IN TREATMENT OF GASTRIC CANCER AND PREMALIGNANT GASTRIC LESIONS**

Prior studies have shown that patients diagnosed with early gastric cancer who did not undergo resection, whether endoscopic or surgical, had a greater 5-year risk for progression to the advanced stage[33,34]. Current guidelines established for the therapy of early gastric cancer recommend resection once the diagnosis has been established[33,34]. Traditional criteria for endoscopic resection of early gastric cancer included adenocarcinoma that was 2 cm or less in diameter without ulceration or lymph node or vascular involvement[35,36]. More recently, this criteria has been expanded as additional studies have shown favorable long term outcomes of endoscopic resection in early gastric cancer, especially with the advances made in endoscopic submucosal dissection (ESD)[35,36]. In fact, multiple studies have now found 5-year survival rates to be nearly 100%[34].

***Endoscopic mucosal resection***

Endoscopic mucosal resection (EMR) is a procedure where a submucosal injection is used to lift the lesion, followed by resection of the lesion using snare. This technique allows for safe removal of intramucosal cancers that are 2 cm or less in diameter[37]. EMR has proven to be an effective treatment for early gastric cancer in terms of long-term outcomes. In one prior study in Japan with 479 cases of gastric cancer treated with EMR, there were no gastric cancer-related deaths during a median follow up period of 38 mo[38]. Notably, the rates of complete resection with EMR decrease with larger lesions with prior studies demonstrating complete resection rates as low as 20%-30% in lesions greater than 2 cm[39].

***ESD***

ESD is a technique in which the submucosal layer is injected to lift the lesion. Following injection, careful dissection of the submucosal layer from the muscular layer is performed using through-the-scope endoscopic knives, until the entire lesion is completely removed[40] (Figure 1). More recently, tools including various endoscopic knives and hemostatic forceps have been developed in order to perform quicker, more secure, and more precise incisions[38,39,41]. ESD has been shown to be more effective at complete resection of larger gastric cancer lesions[34]. In a meta-analysis of 18 observational studies, ESD proved to have a greater incidence of complete and curative resection compared to patients who underwent EMR[42]. ESD also has been associated with a lower risk of recurrence compared to EMR.

***Endoscopic vs surgical resection***

There are no randomized trials yet comparing endoscopic and surgical management of early gastric cancer, though several studies report favorable outcomes in endoscopic resection. Endoscopic resection has been associated with fewer complications and an improved quality of life when compared to surgical resection[43,44], likely because endoscopic resection allows for preservation of the stomach. Notably, studies also suggest that the recurrence rates are significantly higher with endoscopic resection than surgical resection[45].

***Hybrid techniques***

A more recently developed technique for removal of early gastric cancer lesions is laparoscopic endoscopic cooperative surgery (LECS). LECS involves endoscopic mucosal or submucosal dissection with laparoscopic seromuscular resection, with the intention to preserve as much of the normal stomach as possible[45,46]. LECS was initially used for the removal of submucosal tumors, but more recently has been studied for the removal of early gastric cancer[47,48]. It is important to note that with all types of LECS, laparoscopic peri-gastric lymph node dissection is also performed[46].

**ENDOSCOPIC SURVEILLANCE**

***Surveillance of gastric cancer***

At present, there are no established evidence-based gastric cancer surveillance guidelines in the United States. Patients with gastric cancer that was treated with resection continue to have a risk for metachronous gastric cancer. Prior studies report an incidence of metachronous gastric cancer of 3 to 4 percent per year[49]. Japanese guidelines suggest annual or biannual endoscopic surveillance. Other studies have recommended earlier follow-up of 3 mo after resection, followed by gradual spacing to 6 mo and then a year if no lesion identified[49].

***Surveillance of premalignant gastric conditions***

Premalignant gastric conditions include atrophic gastritis and intestinal metaplasia. There are various guidelines for the surveillance of these premalignant conditions. The European Society of Gastrointestinal Endoscopy suggests surveillance intervals depending on the degree and extent of the premalignant lesion[50]. However, the American Gastroenterological Association suggests against endoscopic surveillance in patients with gastric intestinal metaplasia in the general population, and elective surveillance for those with a higher risk of gastric cancer, including family history, certain ethnic minorities, or extensive premalignant conditions[51]. In Japan, patients with atrophic gastritis are recommended to have surveillance endoscopy at 1-2 year intervals[52].

Prior studies report varying rates of progression of dysplastic lesions to gastric cancer, ranging anywhere from 0% to 73% per year[53]. This is in part due to the difference between specific populations such as Asian populations, who appear to have a greater risk of progression. A prior cohort of patients with dysplastic lesions showed progression from high grade dysplasia to gastric cancer in 25% of patients, and progression from low grade dysplasia to gastric cancer in 7% of patients[54]. Based on the current evidence, the International Consensus Project from 2012 has proposed that patients with intestinal metaplasia should be offered endoscopic surveillance every 3 years, while patients with low grade dysplasia should have surveillance imaging every 12 mo. Those with high grade dysplasia are recommended to have surveillance every 6 mo[54].

**CONCLUSION**

Over recent years, many endoscopic advances have been made for the diagnosis and treatment of gastric cancer lesions. Further studies to enhance visualization and diagnosis of early-stage gastric cancer tumors as well as different techniques for removal should be encouraged.

**REFERENCES**

1 **Smyth EC**, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. *Lancet* 2020; **396**: 635-648 [PMID: 32861308 DOI: 10.1016/S0140-6736(20)31288-5]

2 **Thrift AP**, El-Serag HB. Burden of Gastric Cancer. *Clin Gastroenterol Hepatol* 2020; **18**: 534-542 [PMID: 31362118 DOI: 10.1016/j.cgh.2019.07.045]

3 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

4 **Ferlay J**, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer, 2018. [cited 15 July 2022]. Available from: https://gco.iarc.fr/today/fact-sheets-cancers

5 **Kumar S**, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS. Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study. *Gastroenterology* 2020; **158**: 527-536.e7 [PMID: 31654635 DOI: 10.1053/j.gastro.2019.10.019]

6 **Hooi JKY**, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology* 2017; **153**: 420-429 [PMID: 28456631 DOI: 10.1053/j.gastro.2017.04.022]

7 **Huang RJ**, Hwang JH. Improving the Early Diagnosis of Gastric Cancer. *Gastrointest Endosc Clin N Am* 2021; **31**: 503-517 [PMID: 34053636 DOI: 10.1016/j.giec.2021.03.005]

8 **Eusebi LH**, Telese A, Marasco G, Bazzoli F, Zagari RM. Gastric cancer prevention strategies: A global perspective. *J Gastroenterol Hepatol* 2020; **35**: 1495-1502 [PMID: 32181516 DOI: 10.1111/jgh.15037]

9 **Correa P**, Piazuelo MB. The gastric precancerous cascade. *J Dig Dis* 2012; **13**: 2-9 [PMID: 22188910 DOI: 10.1111/j.1751-2980.2011.00550.x]

10 **Yao K**, Uedo N, Kamada T, Hirasawa T, Nagahama T, Yoshinaga S, Oka M, Inoue K, Mabe K, Yao T, Yoshida M, Miyashiro I, Fujimoto K, Tajiri H. Guidelines for endoscopic diagnosis of early gastric cancer. *Dig Endosc* 2020; **32**: 663-698 [PMID: 32275342 DOI: 10.1111/den.13684]

11 **Young E**, Philpott H, Singh R. Endoscopic diagnosis and treatment of gastric dysplasia and early cancer: Current evidence and what the future may hold. *World J Gastroenterol* 2021; **27**: 5126-5151 [PMID: 34497440 DOI: 10.3748/wjg.v27.i31.5126]

12 **Kim JH**, Kim YJ, An J, Lee JJ, Cho JH, Kim KO, Chung JW, Kwon KA, Park DK, Kim JH. Endoscopic features suggesting gastric cancer in biopsy-proven gastric adenoma with high-grade neoplasia. *World J Gastroenterol* 2014; **20**: 12233-12240 [PMID: 25232257 DOI: 10.3748/wjg.v20.i34.12233]

13 **Buxbaum JL**, Hormozdi D, Dinis-Ribeiro M, Lane C, Dias-Silva D, Sahakian A, Jayaram P, Pimentel-Nunes P, Shue D, Pepper M, Cho D, Laine L. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial. *Gastrointest Endosc* 2017; **86**: 857-865 [PMID: 28366441 DOI: 10.1016/j.gie.2017.03.1528]

14 **Rey JF**, Lambert R; ESGE Quality Assurance Committee. ESGE recommendations for quality control in gastrointestinal endoscopy: guidelines for image documentation in upper and lower GI endoscopy. *Endoscopy* 2001; **33**: 901-903 [PMID: 11605605 DOI: 10.1055/s-2001-42537]

15 **Sakai Y**, Eto R, Kasanuki J, Kondo F, Kato K, Arai M, Suzuki T, Kobayashi M, Matsumura T, Bekku D, Ito K, Nakamoto S, Tanaka T, Yokosuka O. Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia: a prospective comparative study. *Gastrointest Endosc* 2008; **68**: 635-641 [PMID: 18561923 DOI: 10.1016/j.gie.2008.03.1065]

16 **Zhao Z**, Yin Z, Wang S, Wang J, Bai B, Qiu Z, Zhao Q. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. *J Gastroenterol Hepatol* 2016; **31**: 1539-1545 [PMID: 26860924 DOI: 10.1111/jgh.13313]

17 **Barbeiro S**, Libânio D, Castro R, Dinis-Ribeiro M, Pimentel-Nunes P. Narrow-Band Imaging: Clinical Application in Gastrointestinal Endoscopy. *GE Port J Gastroenterol* 2018; **26**: 40-53 [PMID: 30675503 DOI: 10.1159/000487470]

18 **Muto M**, Yao K, Kaise M, Kato M, Uedo N, Yagi K, Tajiri H. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). *Dig Endosc* 2016; **28**: 379-393 [PMID: 26896760 DOI: 10.1111/den.12638]

19 **Kakushima N**, Yoshida N, Doyama H, Yano T, Horimatsu T, Uedo N, Yamamoto Y, Kanzaki H, Hori S, Yao K, Oda I, Tanabe S, Yokoi C, Ohata K, Yoshimura K, Ishikawa H, Muto M. Near-focus magnification and second-generation narrow-band imaging for early gastric cancer in a randomized trial. *J Gastroenterol* 2020; **55**: 1127-1137 [PMID: 33021688 DOI: 10.1007/s00535-020-01734-3]

20 **Ang TL**, Pittayanon R, Lau JY, Rerknimitr R, Ho SH, Singh R, Kwek AB, Ang DS, Chiu PW, Luk S, Goh KL, Ong JP, Tan JY, Teo EK, Fock KM. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. *Eur J Gastroenterol Hepatol* 2015; **27**: 1473-1478 [PMID: 26426836 DOI: 10.1097/MEG.0000000000000478]

21 **Uedo N**, Ishihara R, Iishi H, Yamamoto S, Yamamoto S, Yamada T, Imanaka K, Takeuchi Y, Higashino K, Ishiguro S, Tatsuta M. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. *Endoscopy* 2006; **38**: 819-824 [PMID: 17001572 DOI: 10.1055/s-2006-944632]

22 **Desai M**, Boregowda U, Srinivasan S, Kohli DR, Al Awadhi S, Murino A, Yu LHK, Dinis-Ribeiro DM, Sharma P. Narrow band imaging for detection of gastric intestinal metaplasia and dysplasia: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2021; **36**: 2038-2046 [PMID: 34090306 DOI: 10.1111/jgh.15564]

23 **Zhang HP**, Yang S, Chen WH, Hu TT, Lin J. The diagnostic value of confocal laser endomicroscopy for gastric cancer and precancerous lesions among Asian population: a system review and meta-analysis. *Scand J Gastroenterol* 2017; **52**: 382-388 [PMID: 28078907 DOI: 10.1080/00365521.2016.1275770]

24 **Guo YT**, Li YQ, Yu T, Zhang TG, Zhang JN, Liu H, Liu FG, Xie XJ, Zhu Q, Zhao YA. Diagnosis of gastric intestinal metaplasia with confocal laser endomicroscopy in vivo: a prospective study. *Endoscopy* 2008; **40**: 547-553 [PMID: 18618938 DOI: 10.1055/s-2007-995633]

25 **Osawa H**, Yamamoto H. Present and future status of flexible spectral imaging color enhancement and blue laser imaging technology. *Dig Endosc* 2014; **26** Suppl 1: 105-115 [PMID: 24373002 DOI: 10.1111/den.12205]

26 **Jung SW**, Lim KS, Lim JU, Jeon JW, Shin HP, Kim SH, Lee EK, Park JJ, Cha JM, Joo KR, Lee JI. Flexible spectral imaging color enhancement (FICE) is useful to discriminate among non-neoplastic lesion, adenoma, and cancer of stomach. *Dig Dis Sci* 2011; **56**: 2879-2886 [PMID: 21800158 DOI: 10.1007/s10620-011-1831-7]

27 **Ishioka M**, Hirasawa T, Tada T. Detecting gastric cancer from video images using convolutional neural networks. *Dig Endosc* 2019; **31**: e34-e35 [PMID: 30449050 DOI: 10.1111/den.13306]

28 **Yan T**, Wong PK, Qin YY. Deep learning for diagnosis of precancerous lesions in upper gastrointestinal endoscopy: A review. *World J Gastroenterol* 2021; **27**: 2531-2544 [PMID: 34092974 DOI: 10.3748/wjg.v27.i20.2531]

29 **El Abiad R**, Gerke H. Gastric cancer: endoscopic diagnosis and staging. *Surg Oncol Clin N Am* 2012; **21**: 1-19 [PMID: 22098828 DOI: 10.1016/j.soc.2011.09.002]

30 **Huntington CR**, Walsh K, Han Y, Salo J, Hill J. National Trends in Utilization of Endoscopic Ultrasound for Gastric Cancer: a SEER-Medicare Study. *J Gastrointest Surg* 2016; **20**: 154-63; discussion 163-4 [PMID: 26553265 DOI: 10.1007/s11605-015-2988-8]

31 **Mocellin S**, Marchet A, Nitti D. EUS for the staging of gastric cancer: a meta-analysis. *Gastrointest Endosc* 2011; **73**: 1122-1134 [PMID: 21444080 DOI: 10.1016/j.gie.2011.01.030]

32 **Okada K**, Fujisaki J, Kasuga A, Omae M, Yoshimoto K, Hirasawa T, Ishiyama A, Yamamoto Y, Tsuchida T, Hoshino E, Igarashi M, Takahashi H. Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection. *Surg Endosc* 2011; **25**: 841-848 [PMID: 20734082 DOI: 10.1007/s00464-010-1279-4]

33 **Ono H**, Yao K, Fujishiro M, Oda I, Uedo N, Nimura S, Yahagi N, Iishi H, Oka M, Ajioka Y, Fujimoto K. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition). *Dig Endosc* 2021; **33**: 4-20 [PMID: 33107115 DOI: 10.1111/den.13883]

34 **Hasuike N**, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, Oda I, Doyama H, Kaneko K, Hori S, Iishi H, Kurokawa Y, Muto M; Gastrointestinal Endoscopy Group of Japan Clinical Oncology Group (JCOG-GIESG). A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). *Gastric Cancer* 2018; **21**: 114-123 [PMID: 28224238 DOI: 10.1007/s10120-017-0704-y]

35 **Takizawa K**, Ono H, Hasuike N, Takashima A, Minashi K, Boku N, Kushima R, Katayama H, Ogawa G, Fukuda H, Fujisaki J, Oda I, Yano T, Hori S, Doyama H, Hirasawa K, Yamamoto Y, Ishihara R, Tanabe S, Niwa Y, Nakagawa M, Terashima M, Muto M; Gastrointestinal Endoscopy Group (GIESG) and the Stomach Cancer Study Group (SCSG) of Japan Clinical Oncology Group. A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010). *Gastric Cancer* 2021; **24**: 479-491 [PMID: 33161444 DOI: 10.1007/s10120-020-01134-9]

36 **Japanese Gastric Cancer Association**. Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer* 2011; **14**: 113-123 [DOI: 10.1007/s10120-011-0042-4]

37 **Kim GH**, Jung HY. Endoscopic Resection of Gastric Cancer. *Gastrointest Endosc Clin N Am* 2021; **31**: 563-579 [PMID: 34053639 DOI: 10.1016/j.giec.2021.03.008]

38 **Park CH**, Yang DH, Kim JW, Kim JH, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer. *Clin Endosc* 2020; **53**: 142-166 [PMID: 32252507 DOI: 10.5946/ce.2020.032]

39 **Noda M**, Kodama T, Atsumi M, Nakajima M, Sawai N, Kashima K, Pignatelli M. Possibilities and limitations of endoscopic resection for early gastric cancer. *Endoscopy* 1997; **29**: 361-365 [PMID: 9270916 DOI: 10.1055/s-2007-1004216]

40 **Ono H**, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001; **48**: 225-229 [PMID: 11156645 DOI: 10.1136/gut.48.2.225]

41 **Esaki M**, Ihara E, Gotoda T. Endoscopic instruments and techniques in endoscopic submucosal dissection for early gastric cancer. *Expert Rev Gastroenterol Hepatol* 2021; **15**: 1009-1020 [PMID: 33909540 DOI: 10.1080/17474124.2021.1924056]

42 **Tao M**, Zhou X, Hu M, Pan J. Endoscopic submucosal dissection versus endoscopic mucosal resection for patients with early gastric cancer: a meta-analysis. *BMJ Open* 2019; **9**: e025803 [PMID: 31874864 DOI: 10.1136/bmjopen-2018-025803]

43 **Kim SG**, Ji SM, Lee NR, Park SH, You JH, Choi IJ, Lee WS, Park SJ, Lee JH, Seol SY, Kim JH, Lim CH, Cho JY, Kim GH, Chun HJ, Lee YC, Jung HY, Kim JJ. Quality of Life after Endoscopic Submucosal Dissection for Early Gastric Cancer: A Prospective Multicenter Cohort Study. *Gut Liver* 2017; **11**: 87-92 [PMID: 27282267 DOI: 10.5009/gnl15549]

44 **Gotoda T**. Endoscopic resection of early gastric cancer. *Gastric Cancer* 2007; **10**: 1-11 [PMID: 17334711 DOI: 10.1007/s10120-006-0408-1]

45 **Choi KS**, Jung HY, Choi KD, Lee GH, Song HJ, Kim DH, Lee JH, Kim MY, Kim BS, Oh ST, Yook JH, Jang SJ, Yun SC, Kim SO, Kim JH. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. *Gastrointest Endosc* 2011; **73**: 942-948 [PMID: 21392757 DOI: 10.1016/j.gie.2010.12.032]

46 **Min JS**, Seo KW, Jeong SH. Choice of LECS Procedure for Benign and Malignant Gastric Tumors. *J Gastric Cancer* 2021; **21**: 111-121 [PMID: 34234973 DOI: 10.5230/jgc.2021.21.e21]

47 **Abe N**, Mori T, Takeuchi H, Yoshida T, Ohki A, Ueki H, Yanagida O, Masaki T, Sugiyama M, Atomi Y. Laparoscopic lymph node dissection after endoscopic submucosal dissection: a novel and minimally invasive approach to treating early-stage gastric cancer. *Am J Surg* 2005; **190**: 496-503 [PMID: 16105543 DOI: 10.1016/j.amjsurg.2005.05.042]

48 **Goto O**, Takeuchi H, Kitagawa Y, Yahagi N. Endoscopic Submucosal Dissection (ESD) and Related Techniques as Precursors of "New Notes" Resection Methods for Gastric Neoplasms. *Gastrointest Endosc Clin N Am* 2016; **26**: 313-322 [PMID: 27036900 DOI: 10.1016/j.giec.2015.12.006]

49 **Japanese Gastric Cancer Association**. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017; **20**: 1-19 [PMID: 27342689 DOI: 10.1007/s10120-016-0622-4]

50 **Kim B**, Cho SJ. Endoscopic Screening and Surveillance for Gastric Cancer. *Gastrointest Endosc Clin N Am* 2021; **31**: 489-501 [PMID: 34053635 DOI: 10.1016/j.giec.2021.03.004]

51 **Dinis-Ribeiro M**, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ; European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy* 2012; **44**: 74-94 [PMID: 22198778 DOI: 10.1055/s-0031-1291491]

52 **Asaka M**. A new approach for elimination of gastric cancer deaths in Japan. *Int J Cancer* 2013; **132**: 1272-1276 [PMID: 23180638 DOI: 10.1002/ijc.27965]

53 **Yamada H**, Ikegami M, Shimoda T, Takagi N, Maruyama M. Long-term follow-up study of gastric adenoma/dysplasia. *Endoscopy* 2004; **36**: 390-396 [PMID: 15100945 DOI: 10.1055/s-2004-814330]

54 **de Vries AC**, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology* 2008; **134**: 945-952 [PMID: 18395075 DOI: 10.1053/j.gastro.2008.01.071]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** American College of Gastroenterology; American Gastroenterological Association; American Society for Gastrointestinal Endoscopy.

**Peer-review started:** September 23, 2022

**First decision:** November 4, 2022

**Article in press:** February 10, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gao W, China; Miao Y, China **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ

**Figure Legends**



**Figure 1 Endoscopic submucosal dissection of a type 0-IIc lesion found in the antrum.** A: Lesion noted in the antrum; B: Lesion marked for endoscopic submucosal dissection (ESD); C: Lesion removed successfully with ESD; D: Removed specimen, pathology returned as well-differentiated adenocarcinoma with no evidence of malignancy at the margins and no lymph node invasion (courtesy of Dr. Makoto Nishimura).



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**